Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Michael Heuser et al.|Blood|2018Cited by 1k
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 studySylvie Castaigné, Hervé Dombret, Cécile Pautas et al.|The Lancet|2012Cited by 994
A 17-gene stemness score for rapid determination of risk in acute leukaemiaStanley Ng, Jean Wang, Amanda Mitchell et al.|Nature|2016Cited by 916
A Randomized Comparison of All Transretinoic Acid (ATRA) Followed by Chemotherapy and ATRA Plus Chemotherapy and the Role of Maintenance Therapy in Newly Diagnosed Acute Promyelocytic LeukemiaPierre Fenaux, Laurent Degos, Claude Chastang et al.|Blood|1999Cited by 745
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Gert J. Ossenkoppele et al.|Blood|2021Cited by 714